Pharmacogenetics Panel: Psychotropics, with GeneDose Access
Also known as: PGXPSYC GD
Use
The Pharmacogenetics Panel: Psychotropics, with GeneDose Access is used to assess genetic risk of abnormal drug metabolism for a range of psychotropic drugs. This is determined by analyzing polymorphisms in genes that encode for enzymes, such as CYP2B6, CYP2C19, CYP2C9, CYP2D6, and others, that affect the pharmacokinetics and pharmacodynamics of therapeutic agents. It aids in optimizing drug therapy by predicting drug response and assisting in drug selection and dosage decisions, providing clinicians with valuable information for personalized medicine approaches.
Special Instructions
Not provided.
Limitations
Only the targeted genetic variants included in this panel will be detected. Variability in the results may be influenced by factors such as genetic and nongenetic conditions not covered by this test. The evaluation cannot determine if the sample had multiple CYP2D6 gene copies, which may impact metabolism status. Accurate phenotype prediction may be limited by rare genetic variations or the inability to distinguish between one or two copies of certain CYP variants.
New York Approved
Methodology
PCR-based (Sequencing)
Biomarkers
No genes
Gene
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1 mL
Container
Lavender (K2EDTA), pink (K2EDTA), or yellow (ACD solution A or B)
Storage Instructions
Refrigerated
Causes for Rejection
Plasma or serum, specimens collected in sodium heparin or lithium heparin, frozen specimens in glass collection tubes.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 1 week |
| Frozen | 1 month |
Other tests from different labs that may be relevant